Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P M Wallace

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Bioconjugate Chemistry|January 1, 1993
Generation of cytotoxic agents by targeted enzymesP D Senter, P M Wallace, H P Svensson, et al.
Annals of the New York Academy of Sciences|July 21, 1995
In vivo properties of oncostatin MP M Wallace, J F Macmaster, J R Rillema, et al.
Cancer Research|June 1, 1995
In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody beta-lactamase conjugatesH P Svensson, V M Vrudhula, J E Emswiler, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 5, 1999
Regulation of inflammatory responses by oncostatin MP M Wallace, J F MacMaster, K A Rouleau, et al.
Science (New York, N.Y.)|August 7, 1992
Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation moleculeP S Linsley, P M Wallace, J Johnson, et al.
Cancer Research|November 15, 1988
Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkagesP E Thorpe, P M Wallace, P P Knowles, et al.
Journal of the National Cancer Institute|November 1, 1987
Comparison of two anti-Thy 1.1-abrin A-chain immunotoxins prepared with different cross-linking agents: antitumor effects, in vivo fate, and tumor cell mutantsP E Thorpe, D C Blakey, A N Brown, et al.
Cancer Research|May 1, 1988
Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapyM A Ghetie, R D May, M Till, et al.
Cancer Research|November 15, 1987
New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivoP E Thorpe, P M Wallace, P P Knowles, et al.
Blood|April 16, 1998
Characterization of monoclonal antibodies that recognize canine CD34P A McSweeney, K A Rouleau, P M Wallace, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Bioconjugate Chemistry|January 1, 1993
Generation of cytotoxic agents by targeted enzymesP D Senter, P M Wallace, H P Svensson, et al.
Annals of the New York Academy of Sciences|July 21, 1995
In vivo properties of oncostatin MP M Wallace, J F Macmaster, J R Rillema, et al.
Cancer Research|June 1, 1995
In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody beta-lactamase conjugatesH P Svensson, V M Vrudhula, J E Emswiler, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 5, 1999
Regulation of inflammatory responses by oncostatin MP M Wallace, J F MacMaster, K A Rouleau, et al.
Science (New York, N.Y.)|August 7, 1992
Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation moleculeP S Linsley, P M Wallace, J Johnson, et al.
Cancer Research|November 15, 1988
Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkagesP E Thorpe, P M Wallace, P P Knowles, et al.
Journal of the National Cancer Institute|November 1, 1987
Comparison of two anti-Thy 1.1-abrin A-chain immunotoxins prepared with different cross-linking agents: antitumor effects, in vivo fate, and tumor cell mutantsP E Thorpe, D C Blakey, A N Brown, et al.
Cancer Research|May 1, 1988
Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapyM A Ghetie, R D May, M Till, et al.
Cancer Research|November 15, 1987
New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivoP E Thorpe, P M Wallace, P P Knowles, et al.
Blood|April 16, 1998
Characterization of monoclonal antibodies that recognize canine CD34P A McSweeney, K A Rouleau, P M Wallace, et al.
Pageof 4